Is the superiority of apoB over non-HDL-C as a marker of cardiovascular risk in the INTERHEART study due to confounding by related variables?

Journal of Clinical Lipidology

Volumn 7, Issue 6, 2013, Pages 626-631

  Sniderman, Allan D ^a   Islam, Shofiqui ^b   Yusuf, Salim ^b   McQueen, Matthew J ^b  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

ApoB; Cardiovascular risk; Confounder; Discordance; Non HDL C

Indexed keywords

APOLIPOPROTEIN B; BIOLOGICAL MARKER; NON HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE MARKER; ETHNICITY; FEMALE; HEART INFARCTION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

APOB; CARDIOVASCULAR RISK; CONFOUNDER; DISCORDANCE; NON-HDL-C;

ADULT; AGE FACTORS; AGED; APOLIPOPROTEINS B; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; ODDS RATIO; RISK FACTORS; SEX FACTORS;

EID: 84889664367     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2013.08.004     Document Type: Article

References (22)

1. A.D. Sniderman, K. Williams, and J.H. Contois A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk Circ Cardiovasc Qual Outcomes 4 2011 337 345
2. E. Di Angelantonio, P. Gao, and L. Pennells Lipid-related markers and cardiovascular disease prediction. Emerging Risk Factors Collaboration JAMA 30 2012 2499 2506
3. A.D. Sniderman, A.C. St-Pierre, B. Cantin, G.R. Dagenais, J.P. Després, and B. Lamarche Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk Am J Cardiol 91 2003 1173 1177
4. W.C. Cromwell, J.D. Otvos, and M.J. Keyes LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study: implications for LDL management J Clin Lipidol 1 2007 583 592
5. J.D. Otvos, S. Mora, I. Shalaurova, P. Greenland, R.H. Mackey, and D.C. Goff Jr. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number J Clin Lipidol 5 2011 105 113
6. A.D. Sniderman, S. Islam, S. Yusuf, and M.J. McQueen Discordance analysis of apolipoprotein B and non-high density lipoprotein cholesterol as markers of cardiovascular risk in the INTERHEART study Atherosclerosis 225 2012 444 449
7. A. Sniderman, K. Williams, S. Haffner, and N. Sattar Insights from apoB: from better diagnosis & therapy to the Medusa Hypothesis Atheroscler Suppl 5 2004 19 24
8. S. Kathiresan, J.D. Otvos, and L.M. Sullivan Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study Circulation 113 2006 20 29
9. A. Onat, G. Can, G. Hergenc, M. Yazici, A. Karabulut, and S. Albayrak Serum apolipoprotein B predicts dyslipidemia, metabolic syndrome and, in women, hypertension and diabetes, independent of markers of central obesity and inflammation Int J Obes 31 2007 1119 1125
10. M. Faraj, M.-E. Lavoie, L. Messier, J.-P. Bastard, and D. Prud'homme Reduction in serum apoB is associated with reduced inflammation and insulin resistance in post-menopausal women: a MONET study Atherosclerosis 211 2010 682 688
11. M.J. McQueen, S. Hawken, X. Wang INTERHEART study investigators Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study Lancet 372 2008 224 233
12. S. Yusuf, S. Hawken, S. Ounpuu INTERHEART Study Investigators Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study Lancet 364 2004 937 952
13. D.G. Kleinbaum, L.L. Kupper, and H. Morgenstern Epidemiologic Research. Principles and Quantitative Methods 1982 Lifetime Learning Publications Belmont, CA
14. N. Sattar, K. Williams, A.D. Sniderman, R. D'Agostino Jr., and S.M. Haffner Comparison of the associations of apolipoprotein B and non-high-density lipoprotein cholesterol with other cardiovascular risk factors in patients with the metabolic syndrome in the Insulin Resistance Atherosclerosis Study Circulation 110 2004 2687 2693
15. J.H. Ryoo, and S.K. Park Association of apolipoprotein B and incidence of metabolic syndrome in Korean men: a 5-years' follow-up study Atherosclerosis 226 2013 496 501
16. A. Sniderman, M. McQueen, J. Contois, K. Williams, and C.D. Furberg Why is non-high-density lipoprotein cholesterol a better marker of the risk of vascular disease than low-density lipoprotein cholesterol? J Clin Lipidol 3 2010 152 155
17. A. Sniderman, S. Shapiro, D. Marpole, B. Skinner, B. Teng, and P.O. Kwiterovich Jr. Association of coronary atherosclerosis with hyperapobetalipoproteinemia [increased protein but normal cholesterol levels in human plasma low density (beta) lipoproteins] Proc Natl Acad Sci U S A 77 1980 604 608
18. K.J. Williams, and I. Tabas The response-to-retention hypothesis of early atherogenesis Arterioscler Thromb Vasc Biol 15 1995 551 617
19. D.F. Ketelhuth, F.J. Rios, and Y. Wang Identification of a danger-associated peptide from apolipoprotein B100 (ApoBDS-1) that triggers innate proatherogenic responses Circulation 124 2011 2433 2443
20. I. Avraham-Davidi, Y. Ely, and V.N. Pham ApoB-containing lipoproteins regulate angiogenesis by modulating expression of VEGF receptor 1 Nat Med 18 2012 967 973
21. S.M. Grundy Use of emerging lipoprotein risk factors in assessment of cardiovascular risk JAMA 307 2012 2540 2542
22. A. Sniderman, P. Couture, and J. de Graaf Diagnosis and treatment of apolipoprotein B dyslipoproteinemias Nat Rev Endocrinol 6 2010 335 346